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Summary: The lipidomics analysis of mucosal lipids in UC patients revealed disruption in lipid 
composition pattern in active and deep remission UC. Several lipids seem to be involved in the 







































































The onset of ulcerative colitis (UC) is associated with alterations in lipid metabolism, and a disruption 
of the balance between pro and anti-inflammatory molecules. Only a few studies describe the mucosal 
lipid bio-signatures during active UC. Moreover, the dynamics of lipid metabolism in the remission state 
is poorly defined. Therefore, this study aims to characterize mucosal lipid profiles in treatment-naive 
UC patients, and deep remission UC patients, compared to healthy subjects.  
Methods 
Treatment-naive UC patients (n=21), UC patients in deep remission (n=12), and healthy volunteers 
(n=14) were recruited. The state of deep remission was defined by histological and immunological 
remission defined by a normalized TNF-α gene expression. Mucosa biopsies were collected by 
colonoscopy. Lipid analysis was performed by means of ultra-high performance liquid chromatography 
coupled with tandem mass spectrometry (UPLC-MS-MS). In total, 220 lipids from 11 lipid classes were 
identified. 
Results 
The relative concentration of 122 and 36 lipids was altered in UC treatment-naïve patients and UC 
remission patients, respectively, compared with healthy controls. The highest number of significant 
variations were in phosphatidylcholines (PC), ceramides (Cer), and sphingomyelin (SM) composition. 
Multivariate analysis revealed discrimination among the study groups based on the lipid profile. 
Furthermore, changes in PE(38:3), Cer(d18:1/24:0), and Cer(d18:1/24:2), were most distinctive between 
the groups.  
Conclusion 
This study revealed alteration in mucosal lipid composition pattern in treatment-naïve UC and deep 
remission UC. We report several distinctive lipids, which might be involved in the inflammatory 
response in UC, and could reflect the disease state.    
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Inflammatory bowel diseases (IBD) are chronic, relapsing inflammatory disorders in the gastrointestinal 
tract that affects around 1.6 million in the United States and 2.2 million in Europe1. The two major forms 
of IBD, ulcerative colitis (UC) and Crohn’s disease (CD), are characterized by a dysregulated mucosal 
immune response triggered by the intestinal commensal flora2. Several genetic, bacterial, and 
environmental factors appear to lead to the onset of IBD. However, the etiology of IBD is not fully 
understood3. The main treatments of IBD involve steroids and immune-suppressive/modulatory 
medications4, such as anti-TNF-α in severe cases. However, 20-30% of UC patients need surgery at 
some point during their lifetime due to treatment failure or disease complications5, whereas 50-65% of 
UC patients might achieve remission6. Nonetheless, since there is no agreement on the definition of 
‘complete remission’ state, IBD patients might relapse after de-escalating medical treatment7.  
Membrane bio-active lipids modulate the immune response by functioning as intra- and intercellular 
signaling molecules8. For instance, sphingolipids and phospholipids are involved in controlling cellular 
processes, such as proliferation, migration, apoptosis, differentiation, and pro-inflammatory cytokine 
release9, 10. Accordingly, the chronic inflammation seen in IBD is characterized by a disruption of the 
balance between pro- and anti-inflammatory molecules11.  Consequently, UC seems to be associated 
with alterations in the lipid metabolism12, 13. Furthermore, we have recently demonstrated major changes 
in the mucosal concentration of poly-unsaturated fatty acid (PUFA) metabolites in treatment naive UC 
patients14.  
‘Lipidomics’ is defined as the study of the lipids metabolism, composition, and distribution on a large 
scale in a given organism15. Lipidomics has become a powerful tool to understand the pathology and to 
predict the prognosis of complex inflammatory diseases such as, diabetes mellitus16, 17, multiple 
sclerosis18, arthritis19, and Alzheimer disease20. However, there are few IBD studies describing mucosal 
lipid bio-signatures.  
This study aims to describe the mucosal lipid profile in treatment naive UC patients and deep remission 
UC patients compared with healthy subjects. The high throughput lipidomics analysis will help 
capturing the main mucosal lipid composition changes, which reflect the inflammatory state in active 


































































2- Materials and Methods 
2-1-Patients and biopsy collection 
Mucosal biopsies were collected from newly diagnosed treatment naive UC patients (n=21) and UC 
patients in deep remission (n=12). The UC diagnosis was established upon clinical, endoscopic and 
histological criteria defined by the European Crohn and Colitis Organization (ECCO) guidelines.21 The 
degree of inflammation was evaluated during colonoscopy using the scoring system of ulcerative colitis 
disease activity index (UCDAI); UCDAI score of 3-5 is defined as mild, 6-8 as moderate, and 9-12 as 
severe UC22. TNF-α mRNA expression levels were measured by real-time PCR in mucosal biopsies, to 
evaluate the UC activity23. The state of deep remission was defined as endoscopic healed mucosa by 
ECCO 2017 consensus (Mayo score = 0)24 and, additionally, normalized mucosal TNF-α level induced 
by anti-TNF- α treatment25. Subjects performing endoscopy for colonic malignancy screening, with 
normal findings and normal colonic histological examination, served as healthy controls (n=14).  
The biopsies from UC treatment naive patients and the UC remission group were obtained from the 
rectum or sigmoid colon. In patients with active UC, biopsies were taken from the most inflamed 
mucosa, whereas biopsies from the control group were obtained from the rectum. The dry weight of the 
biopsies ranged from 2-8 mg. All biopsies were dry-frozen immediately at -70◦C, and kept at this 
temperature until further analysis. 
2-2-Chemicals and reagents 
N-palmitoyl-d31-D-erythro-sphingosine (16:0-d31 ceramide) was obtained from Avanti Polar 
Lipids (Alabaster, AL, USA). Tripalmitin-1,1,1-13C3 (TG(16:0/16:0/16:0)-13C3) was purchased from 
Larodan (Solna, Sweden). Acetonitrile, formic acid, ammonium formate, chloroform and methanol were 
HPLC grade or higher and purchased from Merck (Darmstadt, Germany). Isopropanol was obtained 
from VWR International (Stockholm, Sweden). Water was purified by a Milli-Q gradient system 
(Millipore, Milford, MA, USA). 
2-3-Lipid Extraction 
Lipid extraction was carried out using a modified Folch extraction26. Briefly, each biopsy was 
transferred to an Eppendorf tube and kept on ice. Then, the extraction mixture (chloroform:methanol 


































































the biopsy in a solid-to-solvent ratio of 1:50 (w/v). The final concentration of tripalmitin-1,1,1-13C3 and 
16:0-d31 ceramide was 0.5 ng/mL and 2 ng/mL respectively.  Two tungsten beads were added to each 
tube, and the samples shaken at 30 Hz for 3 min, and stored at room temperature for 30–60 min. The 
beads were removed, and the samples were further centrifuged at 14,000 rpm and 4 °C for 3 min. 
Finally, the organic phase was collected, split in half and transferred to two micro vials. Samples were 
dried using a vacuum concentrator (MIVac, SP, Warminster, PA, USA) reconstituted in 50 µL of 
acetonitrile. Extracts were stored at −80 °C until analysis.  
2-4-Lipidomics analysis 
Lipidomics analysis was performed with an Infinity 1290 Agilent (Agilent Technologies, Santa Clara, 
CA, USA) ultra-high performance liquid chromatograph coupled with tandem mass spectrometry 
(UHPLC-MS-MS) as previously described26, 27. Briefly, 1 µL of each extract was injected into the 
UHPLC system equipped with an Acquity column (CSH, 2.1× 50 mm, 1.7 µm C18 in combination with 
a 2.1 mm × 5 mm, 1.7 µm VanGuard CSH precolumn (Waters Corporation, Milford, MA, USA),  held 
at 60 °C. The gradient elution buffers were A (60:40 acetonitrile: water, 10 mM ammonium formate 
containing 0.1% formic acid) and B (90:10 2-propanol: acetonitrile, 10 mM ammonium formate 
containing 0.1% formic acid). 15 % B at a flow rate of 0.5 mL/min was set as initial condition, and the 
following gradient was used: B was increased to 30 % in 1.2 min, then to 55% in 0.3 min and held at 55 
% for 3.5 min. It was progressively increased as follows: 72% in 2 min, then 85% in 2.5 min and to 
100% in 0.5 min and was held for 2 minutes. The exact masses of individual lipid molecules were 
detected with an Agilent 6550 Q‐ TOF mass spectrometer equipped with an iFunnel jet stream 
electrospray ion source (Agilent Technologies, Santa Clara, CA, USA). The first batch of extracts was 
analyzed in positive mode. Then, the instrument was switched to the negative mode and the second 
batch of extracts was injected. The flow gas temperature was set at 150°C, the drying gas flow at 12 L 
min-1 and the nebulizer pressure at 40 psi. The sheath gas temperature was set at 350°C and the sheath 
gas flow 1 L min-1. The capillary voltage was set at 4000 V for the positive mode and 2300 V for the 
negative mode. The m/z range was 70 - 1700, and data were collected in centroid mode with an 


































































Targeted data processing was performed using Agilent MassHunter ProFinder B.08.00 software, 
whereas in‐ house databases with exact masses and experimental retention times were used for 
identification. Finally, the extracted features were aligned and matched between samples. In total, 220 
lipid species were identified. These lipid species were from the following lipid classes and subclasses: 
dihydroceramide (dhCer), galactosylceramide (GalCer), ceramide (Cer), sphingomyelin (SM), 
phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylserine (PS), 
phosphatidylinositol (PI), phosphatidylglycerol (PG) lysophosphatidylethanolamine (LPE), and 
lysophosphatidylcholine (LPC). Results were expressed as area under the curve (AUC) values from the 
extracted ion chromatograms of each lipid molecule. Peak areas of individual lipid species were 
normalized by the sum of peak areas of all detected lipid species in the same lipid class. Hence, 
quantitative data for each lipid specie was expressed in percentage as relative concentration to the total 
amount of lipids in the same respective lipid class. 
2-5-Statistical analysis 
Statistical analysis was carried out using MetaboAnalyst 4.0, a web tool for metabolomics data analysis 
(http://www.metaboanalyst.ca/)28 . Undetectable lipids, which represented 1.2% of total reported lipids, 
were assigned a value corresponding to half of the minimum positive value in the original data. Shapiro–
Wilk test of normality was applied, and the data was not found normally distributed. Kruskal–Wallis 
one way analysis of variance test was performed to determine the differences of lipid species between 
treatment naïve UC, remission UC, and control groups. Acquired p-values were adjusted using 
Benjamini and Hochberg FDR method29. Dunn’s test30 was applied as a post hoc test, and significant p-
value cut-off was corrected to 0.017 by Bonferroni multiple comparison method31. The relative lipid 
concentrations were auto scaled in order to adjust the importance of high and low abundance lipids to 
an equal level, and to ease the comparison between the relative lipid concentrations among the study 
groups32. Multivariate analysis was carried out using SIMCA software (version 14.0.0.135559; Umetrics 
AB, Umea, Sweden). Unsupervised multivariate analysis principle component analysis (PCA) was first 
performed to assess the unicity of the lipidome for each of the study group. Then, supervised orthogonal 
partial least squares projection to latent structures-discriminant analysis (OPLS-DA) was employed and 


































































discriminant lipid profile associated with UC treatment-naïve patients. The parameters of the OPLS-DA 
model were described by R2Xcum, R2Ycum and Q2cum, whereas, R2Xcum is the cumulative modeled variation 
in X, R2Ycum is the amount of variation in X correlated to Y (response matrix) and Q2 cum is the cumulative 
predicted ability of the model34.  
3- Ethical Considerations  
 
The Regional Committee of Medical Ethics of North Norway and the Norwegian Social Science Data  
Services approved the study and the storage of biological material under the number (REK NORD 
2012/1349). In addition, all enrolled subjects have signed an informed consent form. 
4- Results 
4-1-Subjects Characteristics 
In total, 21 newly diagnosed treatment naive UC patients, 12 UC patients in state of deep remission and 
14 healthy controls were enrolled in this study. The study group characteristics are described in Table 
1. The UC patients’ disease activity was ranging from mild to severe; 11 patients had mild UC, 4 patients 
had moderate UC and 6 patients had severe UC.  
4-2-Mucosal lipid profiles in treatment-naive UC patients, UC remission patients and controls 
Mucosal lipid profiles in colon biopsies were assessed to determine significant changes in lipid 
composition in treatment naive patients and UC deep remission patients compared to controls.  
Kruskall-Wallis one way analysis of variance with Dunn post hoc was used to compare lipid 
concentrations between all three groups (supplementary Table 1). As summarized in Table 2, among the 
220 lipids included in this study, the relative concentration of 122 and 67 lipids were altered in UC 
treatment naïve patients compared with healthy controls and with UC remission patients respectively. 
However, the mucosal relative concentration of only 26 lipids was changed in UC remission patients 
compared with healthy controls. The lipid classes with the highest number of significant variation in the 
lipid composition were PC, Cer, and SM.  
The greatest change was in the relative mucosal concentration of PE(38:3), which was increased by 37 




































































4-3-Discriminative models for UC state 
The PCA was used as an unbiased multivariate analysis to assess the distinctive lipidomic profile for 
each of the study groups. The PCA score plot (Figure 1A) revealed a clear separation between naïve 
treatment UC patients and healthy controls indicating a specific lipidomic profile for active UC patients. 
However, PCA did not reveal a distinct lipidomic profile for UC remission patients. In addition, PCA 
provided no separation of patients according to age, sex or activity score (data not shown). A supervised 
OPLS-DA was applied to assess the discriminative power of the mucosal lipid profile for UC patients 
(in active and remission state) and healthy controls. A significant OPLS-DA model was obtained with 
maximum separation between the study groups (Figure 1B). The performance parameters describing the 
fitness of all multivariate data analysis models in this study are described in table 3. 
4-4-Discriminative lipids for UC state 
Two OPLS DA models were built, UC treatment-naive vs healthy controls and UC treatment-naive vs 
UC remission. The score plots corresponding to these models are shown in Figures 1C and 1D 
respectively. The shared and unique structure (SUS) plot, constructed from the loading plots of these 
models, identified the main lipid composition pattern in treatment naïve UC patients (Figure 2A). The 
SUS plot revealed that the lipidomic profile in UC treatment-naïve patients is mainly characterized by 
high levels of very long fatty acid chain (VLCFA) ceramides, specifically those with 24 carbons chain-
length (C24). In addition, several PCs and PEs were elevated, mainly PE(38:3). 
Based on the SUS-plot, 3 candidate lipids were selected for further investigation. These lipids were 
PE(38:3), Cer(d18:1/24:0), and Cer(d18:1/24:2). The discriminative ability of these lipids was 
confirmed by comparing the ion chromatograms at the specific retention times (RT) for each of these 
lipids among the study groups. As shown in Figure 2, PE(38:3) was only detected in UC patients colonic 
mucosa (both UC active and UC remission patients). Moreover, PE(38:3) is clearly increased in 
inflamed mucosa (UC active) compared with healed mucosa (UC remission). In addition, the levels of 
Cer(d18:1/24:0) and Cer(d18:1/24:2) were low in healed mucosa, and increased in a step wise manner 





































































This study provides a unique and detailed characterization of mucosal lipid profiles in treatment naive 
newly diagnosed and deep remission UC patients. Previous studies were restricted to investigate lipid 
profiles in other matrices, specifically plasma35 and stool36 or in animal models with experimentally 
induced colitis 37. Moreover, previous studies were performed on a mix of treated and untreated UC 
patients, which might lead to less specific profiles, regarding the differences between active disease and 
remission demonstrated in the present data. Therefore, only treatment naive UC patients were recruited 
as active inflammation group in our study. The state of remission was based on a combination of 
normalized TNF gene expression, histologic, and endoscopic criteria (Mayo = 0). This allows the 
detection of variations in the lipid composition that are exclusively associated with UC development. 
To our knowledge, this is the first published study of mucosal lipid profiles in UC patients. We have 
investigated 220 lipids from 11 different lipid classes. The lipid profiling revealed major disruption in 
the mucosal lipid composition in active UC patients compared with healthy controls.  
The most significant finding in the current study is the observed changes in the PE(38:3) concentration 
in response to the mucosal inflammatory state. This lipid was only detected in the UC patients’ mucosa. 
Notably, the mucosal levels consistently decrease in the remission state compared with the active disease 
state. Despite being poorly described in UC, high level of serum PE(38:3) was previously found 
associated with diabetes and prediabetes38. Moreover, increased level of PE has been linked with 
Alzheimer disease39. In addition, due to the role of PE in apoptosis, PE has been suggested as a target 
for cell death imaging, and a marker for TNF-induced inflammation40, 41. The plausible role of PE(38:3) 
in promoting inflammation could make it useful in monitoring the development of UC. However, this 
needs to be confirmed by larger studies, which also investigate the presence of PE(38:3) in other kinds 
of matrices such as feces, serum, or urine. 
In the present data, Cer(d18:1/24:2) and Cer(d18:1/24:0) increase according to the UC state from 
remission to active inflammation. These two ceramides, classified as very long chain fatty acid 
sphingolipids (VLCFAs), are necessary for the neutrophils functions42. The present research is the first 


































































involved in other inflammatory diseases. For instance, higher levels of Cer(d18:1/24:2) and 
Cer(d18:1/24:0) were detected in synovial fluid in rheumatoid arthritis and osteoarthritis patients43. 
Moreover, a high serum level of Cer(d18:1/24:0) has been associated with a high risk of dementia in 
Alzheimer disease, and increased with the disease severity44. 
The highest significant variations in the lipid composition were detected in Cer, SM and PC profiles. 
Previously, lipids analysis on experimentally induced IBD have revealed changes in sphingolipids (Cer 
and SM)45 and the PC profile46. Changes in the PC profile demonstrate the impairment in the mucus 
barrier during IBD47. Furthermore, changes in sphingolipids could be explained by the suggested 
harmful role of ceramides in IBD, mainly by activating immune cells and triggering apoptosis9. 
Consequently, tissue ceramide levels were found elevated in a stepwise manner from control to 
remission, mild, and moderate/severe IBD patients48. In addition, it has been previously found that IL-
1 stimulates ceramide accumulation in intestinal epithelial cells49. Moreover, previous studies revealed 
major changes in sphingolipid metabolic pathways during IBD50, 51. The current study has revealed a 
distinct lipid profile in UC deep remission patients, although being selected based on mucosal healing 
and immunological remission52. Accordingly, the mucosal concentrations of 26 lipid species, mainly 
sphingolipids, were altered compared to healthy control. This finding could be of clinical utility in 
defining treatment goals and end-point parameters in the context of personalized medicine. Furthermore, 
it supports previously published data on the sphingolipid metabolism as a therapeutic target in IBD53, 54. 
Moreover, this suggests the lipidomics profiling as a tool to improve the definition of UC remission in 
the current guidelines and scoring systems.  
The present work is purely descriptive. Moreover, the relatively small sample size in the current study 
disqualify subgroup analysis according to the severity of the diseases. Furthermore, the reported results 
are expletory and need to be validated by a larger cohort. In addition, we suggest exploring the mucosal 





































































The present report describe an in depth the mucosal lipid profile in UC via full lipidomic analysis of 
colon biopsies taken from UC treatment naive patients, UC patients in state of deep remission, and 
healthy subjects. The analysis of mucosal lipids demonstrated alteration in the lipid composition in 
active and deep remission UC, and it revealed the involvement of several lipids in the mucosal 
inflammatory processes in UC.  
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Figure 1. Multivariate analysis of the mucosal lipid profiles. Each subject was labeled according to the 
corresponding study group. Figure 2.A: 2D Principle component analysis (PCA) score plots. The 
variation explained by PC1 and PC2 were 25.1% and 18.5%, respectively. Figure 2.B: The score plot of 
the OPLS-DA model built from the lipid profile of the three study groups. Figure 2.C and Figure 2.D: 
Score plot of the OPLS-DA model built from the lipid profile of UC treatment naïve vs healthy controls 
and UC treatment naïve vs UC remission patients. 
 
Figure 2: Figure 2.A SUS-plot constructed using the correlation coefficient (p (corr)) from the loading 
plots of the two OPLS DA models, UC treatment-naïve vs Controls (X-axis) and UC treatment-naïve vs 
UC remission (Y-axis). The lipids are labelled according to lipid class. The highlighted region contains 
lipids that are elevated in UC treatment naïve patients. For simplicity, only a few lipids are displayed 
with full name. The same figure with all full names of the lipids is provided in the supplementary data 
section (supplementary Figure 1). Figures 3B, 3C and 3D represent the extracted ion chromatograms of 
PE(38:3), Cer(d18:1/24:0), and Cer(d18:1/24:2), respectively. The peaks are aligned and colored 
according to the study group. Black is the treatment-naïve UC group, red is UC deep remission group, 













































































Table 1. Description of study group characteristics.  







copies/μg of total RNA 
Active UC (debut)  21 42 (20-68) 6/15 17670 (4600-30700) 
Healthy controls 14 54 (26-83) 5/9 5400 (1800-13600) 
UC remission 12 48 (23-71) 4/8 4675 (800-7300) 
     *Data are presented as mean (range) 
 
Table 2: Summary of altered lipids associated with UC state identified by Kruskall-Wallis and Dunn 
post-hoc analysis 
 
    Number of lipids   
Lipid Class 
Total number of 
annotated lipids 
Active UC vs 
Healthy Control 
Active UC vs 
UC Remission  
UC Remission vs 
Healthy Control 
Phosphatidylcholine 55 40 18 4 
Ceramide 27 14 10 5 
Phosphatidylserine 20 11 8 1 
Phosphatidylinositol 14 9 5 1 
Phosphatidylethanolamine 25 10 8 3 
Galactosylceramide 20 13 5 3 
Sphingomyelin 19 10 7 2 
Dihydroceramide 17 7 5 7 
Phosphatidylglycerol 6 1 1 - 
Lysophasphatidylcholine 12 4 - 2 
Lysophasphatidylethanolamine 5 3 - - 




Table 3: Summary performance parameters of multivariate data analysis models applied in this study.   
Data set Model Components R2Xcum R2Ycum Q2 cum 
All 3 study groups PCA 2 0.436 - 0.302 
All 3 study groups 
 
OPLS-DA 2 + 1* 0.553 0.762 0.580 
Active UC vs UC 
Remission 
 
OPLS-DA 1+1* 0.403 0.868 0.788 
UC Remission vs 
Healthy Control 
OPLS-DA 1+1* 0.332 0.756 0.584 
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Counts vs. Acquisition Time (min)
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Counts vs. Acquisition Time (min)
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Active UC vs Healthy Control Active UC vs Remission UC Remission UC vs Healthy Control 
Fold change P.value** Fold change P.value** Fold change P.value** 
Cer(d18:0/16:0) 0.160 0.91 0.702 0.79 0.018 1.16 0.067 
Cer(d18:0/17:0) 0.099 0.83 0.063 0.74 0.016 1.12 0.565 
Cer(d18:0/18:0) <0.001 1.64 <0.001 1.60 <0.001 1.02 0.998 
Cer(d18:0/19:0) 1.000 1.14 0.279 0.91 0.625 1.25 0.162 
Cer(d18:0/20:0) <0.001 1.86 <0.001 1.68 0.001 1.11 0.621 
Cer(d18:0/22:0) <0.001 1.85 <0.001 1.92 <0.001 0.96 0.739 
Cer(d18:0/22:1) 0.079 1.31 0.025 1.34 0.024 0.98 0.912 
Cer(d18:0/23:0) 0.012 0.83 0.045 1.36 0.095 0.61 0.001 
Cer(d18:0/23:1) 0.457 1.41 0.118 0.77 0.643 1.84 0.072 
Cer(d18:0/23:3) 0.452 1.45 0.075 1.29 0.161 1.12 0.784 
Cer(d18:0/24:0) 0.012 0.94 0.357 1.65 0.009 0.57 0.001 
Cer(d18:0/24:1) 0.011 1.00 0.349 1.58 0.009 0.63 0.001 
Cer(d18:0/25:0) <0.001 0.53 <0.001 1.05 0.842 0.50 <0.001 
Cer(d18:0/25:1) 0.002 0.68 0.006 1.49 0.139 0.46 <0.001 
Cer(d18:0/26:0) 0.008 0.77 0.005 1.28 0.419 0.61 0.001 
Cer(d18:0/26:1) 0.000 0.64 <0.001 1.22 0.273 0.52 <0.001 
Cer(d18:1/14:0) 0.000 0.56 0.002 0.38 <0.001 1.47 0.407 
Cer(d18:1/15:1)ox 1.000 0.51 0.736 0.64 0.986 0.80 0.755 
Cer(d18:1/16:0) 0.006 0.94 0.594 0.53 0.001 1.75 0.007 
Cer(d18:1/16:1) 0.000 0.32 <0.001 0.38 <0.001 0.83 0.317 
Cer(d18:1/17:0) 0.001 0.73 0.050 0.54 <0.001 1.34 0.061 
Supp. Table 1
Cer(d18:1/18:0) 0.330 1.04 0.643 0.80 0.086 1.29 0.047 
Cer(d18:1/18:1) 0.096 0.83 0.037 0.60 0.024 1.39 0.803 
Cer(d18:1/19:0) 0.111 1.21 0.022 0.96 0.833 1.26 0.028 
Cer(d18:1/20:0) 0.001 1.50 <0.001 1.23 0.024 1.23 0.162 
Cer(d18:1/20:1) 0.014 1.50 0.001 1.13 0.341 1.33 0.047 
Cer(d18:1/20:3) 1.000 0.96 0.523 1.06 0.682 0.90 0.348 
Cer(d18:1/20:5) 0.011 0.93 0.805 0.58 0.001 1.61 0.007 
Cer(d18:1/22:0) 0.000 1.50 <0.001 1.05 0.338 1.42 0.002 
Cer(d18:1/22:1) 0.000 2.31 <0.001 1.92 <0.001 1.20 0.332 
Cer(d18:1/22:6) 0.772 0.80 0.159 0.82 0.185 0.98 0.988 
Cer(d18:1/23:0) 1.000 1.07 0.212 1.00 0.998 1.07 0.275 
Cer(d18:1/23:1) <0.001 1.63 <0.001 1.47 0.001 1.11 0.326 
Cer(d18:1/24:0) <0.001 1.51 <0.001 1.15 0.052 1.31 0.006 
Cer(d18:1/24:1) <0.001 1.59 <0.001 1.33 0.003 1.19 0.106 
Cer(d18:1/24:1)ox <0.001 5.96 <0.001 4.28 <0.001 1.39 0.387 
Cer(d18:1/24:2) <0.001 2.31 <0.001 1.76 <0.001 1.31 0.141 
Cer(d18:1/25:0) 1.000 1.04 0.672 1.08 0.319 0.96 0.586 
Cer(d18:1/25:1) 0.070 1.18 0.011 1.15 0.058 1.03 0.623 
Cer(d18:1/25:2) 0.036 1.31 0.005 1.03 0.946 1.27 0.018 
Cer(d18:1/26:0) 0.074 1.24 0.011 0.99 0.967 1.25 0.029 
Cer(d18:1/26:1) 0.002 1.31 <0.001 1.06 0.797 1.23 0.003 
Cer(d18:1/26:2) <0.001 2.22 <0.001 1.55 0.022 1.43 0.025 
GalCer(d18:0/22:0) 0.013 0.59 0.001 0.90 0.484 0.66 0.027 
GalCer(d18:1/14:0) 1.000 1.16 0.344 1.13 0.367 1.03 1.000 
GalCer(d18:1/16:0) 0.001 0.66 0.001 0.45 0.001 1.48 0.858 
GalCer(d18:1/18:0)ox <0.001 0.50 <0.001 0.64 0.001 0.77 0.068 
GalCer(d18:1/20:0) 0.047 1.57 0.015 0.91 0.604 1.72 0.009 
GalCer(d18:1/20:3) 0.001 5.37 <0.001 2.10 0.348 2.55 0.007 
GalCer(d18:1/22:0) 0.002 1.48 <0.001 1.00 0.979 1.47 0.002 
GalCer(d18:1/22:0)ox 0.002 0.67 <0.001 0.87 0.297 0.78 0.015 
GalCer(d18:1/22:1) 0.032 1.50 0.003 1.13 0.558 1.33 0.040 
GalCer(d18:1/23:0) 1.000 0.89 0.384 0.83 0.226 1.07 0.726 
GalCer(d18:1/24:0) 0.185 1.35 0.019 1.11 0.445 1.21 0.173 
GalCer(d18:1/24:0)ox 0.000 0.55 <0.001 0.72 0.078 0.76 0.017 
GalCer(d18:1/2:41) 0.000 2.66 <0.001 1.88 0.007 1.41 0.139 
GalCer(d18:1/24:1)ox 0.068 0.90 0.129 1.18 0.123 0.77 0.006 
GalCer(d18:1/25:0)ox 0.000 0.45 <0.001 0.64 0.012 0.70 0.020 
GalCer(d18:1/25:1)ox 0.000 0.60 <0.001 0.75 0.016 0.80 0.033 
GalCer(d18:1/26:0)ox 0.014 0.58 0.001 0.90 0.570 0.64 0.022 
GalCer(d18:1/26:1) 0.179 0.73 0.021 0.94 0.737 0.77 0.088 
GalCer(d18:1/26:1)ox 0.094 0.85 0.093 1.19 0.218 0.72 0.009 
GalCer(d18:1/28:1)ox 0.825 0.90 0.110 0.88 0.635 1.02 0.334 
LPC(14:0) 0.004 2.00 <0.001 1.13 0.361 1.77 0.019 
LPC(16:0) 0.291 1.06 0.036 1.08 0.203 0.98 0.504 
LPC(16:1) 0.007 1.65 0.001 1.13 0.983 1.46 0.005 
LPC(17:0) 0.693 0.99 0.146 1.00 0.165 0.99 0.998 
LPC(18:0) 1.000 0.98 0.684 0.98 0.260 1.00 0.498 
LPC(18:1) 0.472 1.02 0.778 1.23 0.062 0.82 0.142 
LPC(18:2) 0.002 1.71 <0.001 1.32 0.043 1.29 0.135 
LPC(20:0) 0.365 1.17 0.912 0.83 0.064 1.41 0.072 
LPC(20:5) 0.009 0.43 0.001 1.00 0.671 0.43 0.012 
LPC(22:6) 0.246 0.65 0.044 1.04 0.893 0.63 0.059 
LPC(O-16:1) 0.101 2.03 0.039 0.06 0.497 32.56 0.015 
LPC(O-18:0) 0.140 0.50 0.016 1.00 0.689 0.50 0.081 
LPE(16:0) 0.031 1.47 0.003 2.34 0.447 0.63 0.053 
LPE(16:1) 0.345 7.99 0.061 6.58 0.121 1.21 0.828 
LPE(18:0) 0.049 1.23 0.007 2.71 0.880 0.45 0.026 
LPE(18:2) 1.000 2.90 0.533 3.35 0.613 0.86 0.311 
LPE(20:0) 0.000 0.37 <0.001 0.40 <0.001 0.93 0.635 
PC(30:1) 0.000 2.49 <0.001 1.58 0.029 1.58 0.078 
PC(31:1) 0.001 1.49 <0.001 1.27 0.018 1.17 0.254 
PC(32:0) 0.000 1.69 <0.001 1.34 0.008 1.26 0.010 
PC(32:1) 0.009 1.27 0.001 1.03 0.476 1.24 0.023 
PC(32:2) 0.008 1.71 0.001 1.25 0.130 1.37 0.105 
PC(33:0) 0.000 1.90 <0.001 1.57 0.001 1.21 0.137 
PC(33:1) 1.000 1.02 0.770 1.09 0.557 0.94 0.426 
PC(33:2) 0.001 0.68 <0.001 0.74 0.003 0.93 0.638 
PC(34:0) 0.000 1.93 <0.001 1.64 <0.001 1.18 0.541 
PC(34:1) 0.000 0.83 <0.001 0.82 0.002 1.01 0.646 
PC(34:2) 0.000 0.78 <0.001 0.80 <0.001 0.98 0.461 
PC(34:3) 1.000 0.90 0.472 0.97 0.889 0.93 0.615 
PC(34:4) 0.032 1.79 0.003 1.25 0.177 1.43 0.162 
PC(35:0) 0.002 1.80 <0.001 1.52 0.010 1.18 0.418 
PC(35:1) 0.094 0.84 0.029 1.12 0.604 0.75 0.017 
PC(35:2) 0.004 0.70 <0.001 0.91 0.424 0.77 0.016 
PC(35:3) 0.000 0.57 <0.001 0.67 0.006 0.84 0.163 
PC(35:4) 0.001 2.50 <0.001 1.72 0.014 1.45 0.212 
PC(36:1) 1.000 1.01 0.759 1.16 0.189 0.88 0.348 
PC(36:2) 0.000 0.79 <0.001 0.84 <0.001 0.94 0.123 
PC(36:3) 0.000 0.82 <0.001 0.91 0.241 0.90 0.002 
PC(36:4) 0.004 1.26 <0.001 1.02 0.750 1.24 0.006 
PC(36:5) 0.182 1.15 0.344 1.52 0.018 0.76 0.178 
PC(36:6) 1.000 0.94 0.996 1.18 0.242 0.79 0.280 
PC(37:2) 0.036 1.34 0.011 1.39 0.016 0.96 0.996 
PC(38:3) 0.001 1.68 <0.001 1.55 0.005 1.09 0.486 
PC(38:4) 0.001 1.54 <0.001 1.07 0.715 1.44 0.003 
PC(38:5) 0.000 1.43 <0.001 1.22 0.040 1.17 0.058 
PC(38:6) 0.020 1.45 0.003 1.33 0.027 1.09 0.578 
PC(38:7) 0.874 1.16 0.354 1.30 0.127 0.89 0.554 
PC(40:4) 0.000 2.59 <0.001 2.18 0.003 1.19 0.458 
PC(40:5) 0.000 2.07 <0.001 1.49 0.057 1.39 0.057 
PC(40:6) 0.016 1.49 0.001 1.16 0.185 1.28 0.105 
PC(40:7) 0.152 1.00 0.900 1.20 0.021 0.83 0.045 
PC(40:8) 0.019 1.35 0.067 1.79 0.002 0.75 0.209 
PC(42:5) 0.000 2.58 <0.001 2.52 0.001 1.02 0.968 
PC(O-32:0) 0.000 2.07 <0.001 1.68 0.001 1.23 0.303 
PC(O-32:1) 0.015 1.50 0.003 1.43 0.016 1.05 0.716 
PC(O-34:0) 1.000 1.10 0.556 1.16 0.207 0.95 0.519 
PC(O-34:1) 0.202 1.22 0.208 1.49 0.022 0.82 0.318 
PC(O-34:2) 0.001 0.59 <0.001 0.82 0.202 0.73 0.017 
PC(O-34:3) 0.001 0.63 <0.001 0.86 0.196 0.73 0.019 
PC(O-36:2) 0.010 0.72 0.013 1.24 0.250 0.58 0.001 
PC(O-36:3) 0.000 0.37 <0.001 0.58 0.008 0.63 0.018 
PC(O-36:4) 0.002 1.44 <0.001 1.22 0.060 1.18 0.119 
PC(O-36:5) 0.013 1.27 0.001 1.05 0.581 1.21 0.020 
PC(O-36:6) 0.778 0.77 0.105 0.91 0.386 0.85 0.532 
PC(O-38:2) 1.000 1.35 0.239 1.26 0.472 1.08 0.711 
PC(O-38:3) 0.000 1.68 0.010 2.05 <0.001 0.82 0.127 
PC(O-38:4) 0.022 1.80 0.006 1.54 0.016 1.17 0.832 
PC(O-38:5) 0.114 1.26 0.013 1.15 0.126 1.09 0.445 
PC(O-38:6) 0.001 1.52 <0.001 1.42 0.003 1.07 0.659 
PC(O-38:7) 0.264 1.35 0.028 1.18 0.330 1.15 0.302 
PC(O-40:4) 0.000 3.80 <0.001 2.77 0.001 1.37 0.458 
PC(O-40:6) 0.000 1.82 <0.001 1.59 0.001 1.14 0.553 
PE(32:0) 0.028 1.53 0.003 1.13 0.630 1.35 0.030 
PE(32:1) 0.183 1.43 0.069 0.77 0.481 1.86 0.025 
PE(32:2) 0.003 1.45 0.076 0.72 0.017 2.02 <0.001 
PE(34:0) 0.018 1.43 0.002 1.32 0.094 1.08 0.221 
PE(34:1) 0.000 0.67 <0.001 0.79 0.010 0.86 0.107 
PE(34:2) 0.107 0.82 0.053 0.80 0.020 1.03 0.665 
PE(36:1) 0.174 0.92 0.036 1.07 0.794 0.86 0.038 
PE(36:2) 0.564 0.87 0.112 0.96 0.820 0.91 0.109 
PE(36:3) 1.000 0.93 0.988 1.00 0.509 0.93 0.553 
PE(36:4) 0.002 1.54 <0.001 1.08 0.561 1.42 0.006 
PE(36:5) 0.738 0.81 0.119 1.05 0.975 0.77 0.180 
PE(38:0) 0.026 0.83 0.002 0.93 0.107 0.88 0.235 
PE(38:2) 0.142 1.31 0.014 1.10 0.408 1.20 0.161 
PE(38:3) 0.000 37.48 <0.001 1.96 0.009 19.13 0.020 
PE(38:4) 0.002 1.46 <0.001 1.16 0.138 1.26 0.052 
PE(38:5) <0.001 2.17 <0.001 1.80 0.005 1.20 0.205 
PE(38:6) 1.000 1.03 0.516 0.89 0.232 1.16 0.596 
PE(40:4) <0.001 2.66 <0.001 1.99 0.005 1.33 0.168 
PE(40:6) 1.000 1.13 0.751 0.98 0.490 1.16 0.361 
PE(40:7) 0.790 1.25 0.114 1.18 0.324 1.06 0.632 
PE(42:5) 0.022 6.27 0.003 1.16 0.844 5.42 0.016 
PE(O-34:2) 0.005 0.33 <0.001 0.48 0.036 0.69 0.258 
PE(O-36:2) <0.001 0.47 <0.001 0.84 0.364 0.56 0.001 
PE(O-38:5) <0.001 0.30 <0.001 0.45 0.001 0.65 0.185 
PG(34:1) 0.341 0.92 0.038 1.04 0.557 0.89 0.201 
PG(36:1) 0.633 1.08 0.472 0.90 0.225 1.19 0.080 
PG(38:6) 0.000 0.32 <0.001 0.38 0.001 0.84 0.413 
PG(40:7) 0.236 0.71 0.029 0.95 0.753 0.74 0.104 
PG(40:8) 0.967 0.81 0.144 0.95 0.827 0.86 0.280 
PG(45:8) 0.357 1.30 0.046 1.20 0.217 1.09 0.538 
PI(34:0) <0.001 2.25 <0.001 1.40 0.258 1.61 0.003 
PI(34:1) 0.013 0.75 0.001 0.82 0.039 0.92 0.377 
PI(34:2) 0.010 0.72 0.002 0.73 0.016 0.99 0.606 
PI(35:2) <0.001 0.94 0.001 0.95 <0.001 1.00 0.547 
PI(36:2) <0.001 0.56 <0.001 0.74 0.036 0.76 0.012 
PI(36:3) 1.000 0.88 0.251 0.92 0.850 0.95 0.405 
PI(38:2) 0.504 0.87 0.452 0.71 0.059 1.23 0.281 
PI(38:3) 0.001 1.57 0.001 1.61 0.001 0.97 0.940 
PI(38:4) <0.001 1.23 <0.001 1.07 0.139 1.15 0.021 
PI(38:5) 0.367 1.10 0.205 1.20 0.049 0.92 0.483 
PI(38:6) 0.549 0.76 0.105 0.81 0.153 0.94 0.916 
PI(40:4) <0.001 1.97 <0.001 1.63 0.002 1.21 0.111 
PI(40:5) <0.001 1.59 <0.001 1.45 0.002 1.10 0.309 
PI(40:6) 1.000 1.13 0.622 1.23 0.400 0.91 0.732 
PS(32:1) 0.689 0.08 0.094 0.50 0.771 0.16 0.230 
PS(34:0) <0.001 0.58 <0.001 0.67 0.001 0.86 0.126 
PS(34:1) <0.001 0.46 <0.001 0.36 <0.001 1.25 0.769 
PS(36:1) 0.008 0.70 0.002 0.72 0.012 0.98 0.680 
PS(36:2) 0.101 0.85 0.080 0.74 0.014 1.15 0.473 
PS(36:3) 0.079 0.88 0.275 0.67 0.007 1.32 0.128 
PS(36:4) 1.000 0.88 0.342 0.82 0.190 1.07 0.711 
PS(38:1) 0.515 1.33 0.073 1.17 0.229 1.14 0.641 
PS(38:2) 0.012 0.77 0.005 0.72 0.007 1.07 0.967 
PS(38:3) 0.032 1.45 0.017 1.50 0.009 0.97 0.766 
PS(38:4) 0.049 0.72 0.025 0.51 0.012 1.40 0.739 
PS(38:5) 0.001 5.14 <0.001 3.64 0.001 1.41 0.930 
PS(39:7) 0.036 0.68 0.003 0.86 0.102 0.79 0.288 
PS(40:0) 0.017 0.84 0.015 1.40 0.311 0.60 0.002 
PS(40:2) 0.007 0.68 0.001 0.80 0.026 0.86 0.398 
PS(40:3) 1.000 1.00 0.785 1.71 0.996 0.58 0.814 
PS(40:4) 0.007 2.00 0.001 1.22 0.427 1.64 0.022 
PS(40:5) 0.072 1.53 0.006 1.26 0.240 1.21 0.190 
PS(40:6) 1.000 1.07 0.255 0.83 0.197 1.30 0.849 
PS(40:7) 0.048 0.78 0.004 0.91 0.385 0.86 0.086 
SM(d18:0/14:0) 0.006 1.39 0.006 1.50 0.002 0.93 0.640 
SM(d18:0/16:0) 0.070 0.76 0.008 0.84 0.092 0.91 0.442 
SM(d18:0/18:0) 1.000 1.03 0.622 0.97 0.609 1.06 0.367 
SM(d18:1/14:0) 0.010 1.46 0.002 1.36 0.018 1.07 0.575 
SM(d18:1/15:0) 0.105 1.24 0.045 1.29 0.023 0.96 0.739 
SM(d18:1/16:0) 0.170 0.90 0.042 0.88 0.051 1.03 0.993 
SM(d18:1/16:1) <0.001 1.90 <0.001 1.61 0.004 1.18 0.345 
SM(d18:1/18:0) 0.000 0.74 0.001 0.62 <0.001 1.19 0.256 
SM(d18:1/18:0)ox 0.331 1.08 0.376 1.19 0.036 0.91 0.249 
SM(d18:1/18:1) 0.019 0.81 0.016 0.64 0.004 1.26 0.602 
SM(d18:1/19:0) 0.022 1.08 0.286 1.42 0.002 0.76 0.051 
SM(d18:1/20:0) 1.000 0.92 0.526 0.90 0.593 1.02 0.949 
SM(d18:1/21:1) 0.004 0.75 0.006 1.25 0.233 0.60 <0.001 
SM(d18:1/22:0) 0.926 1.17 0.237 0.94 0.652 1.24 0.146 
SM(d18:1/23:2) 0.000 1.88 <0.001 1.79 <0.001 1.05 0.984 
SM(d18:1/24:0) 0.015 1.33 0.192 1.68 0.001 0.79 0.065 
SM(d18:1/24:1) 0.003 1.44 <0.001 1.29 0.018 1.12 0.351 
SM(d18:1/24:2) <0.001 1.66 <0.001 1.40 0.004 1.18 0.207 
SM(d18:1/25:1) 0.008 0.75 0.005 1.17 0.466 0.64 0.002 
  
* Kruskall Wallis p values adjusted by Benjamini-Hocheberg method 
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Supp. Figure 1
